<DOC>
	<DOCNO>NCT00449605</DOCNO>
	<brief_summary>The primary objective demonstrate , 52 week treatment , non-inferiority rimonabant 20 mg daily ( od ) versus glimepiride od reduce glycosylated haemoglobin ( HbA1c ) overweight/obese patient type 2 diabetes adequately control metformin stable dose ( â‰¥ 1500 mg/day ) least 3 month . The main secondary objective assess effect rimonabant comparison glimepiride body weight HDL-Cholesterol long-term safety tolerability rimonabant comparison glimepiride .</brief_summary>
	<brief_title>A Glycemic Control Evaluation Glimepiride Versus Rimonabant Top Metformin Type 2 Diabetes</brief_title>
	<detailed_description>The total duration per patient approximately 65 week include 52-week double-blind treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Patients legal age Body Mass Index &gt; 27kg/m2 Type 2 diabetes define World Health Organization ( WHO ) criterion , treat metformin least 6 month stable dose metformin &gt; =1500 mg/day least three month HbA1c &gt; =7 % &lt; =9 % screen visit Weight loss &gt; 5 kg within three month prior screen Presence clinically significant endocrine disease accord Investigator Presence type 1 diabetes Presence history cancer within past 5 year exception adequatelytreated localized basal cell skin cancer situ uterine cervical cancer Previous participation clinical study rimonabant Absence effective medical contraceptive method female childbearing potential Within 3 month prior screen visit : use oral antidiabetic drug ( metformin ) and/or insulin , antiobesity drug drug weight reduction Within 2 month prior screen visit : administration systemic longacting corticosteroid prolong use ( one week ) systemic corticosteroid , change lipid lower treatment Presence severe medical psychological condition chronic conditions/infections opinion Investigator would compromise patient 's safety successful participation study , include uncontrolled serious psychiatric illness The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Metformin</keyword>
</DOC>